Shanghai Henlius Biotech, Inc.
http://www.henlius.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Shanghai Henlius Biotech, Inc.
BIO 2022 Notebook: How Is Industry Faring In Turbulent Times?
News and views from day one of the BIO annual meeting include reflections on how the biopharma industry is adjusting to current conditions. EY's annual Beyond Borders reports predicts continued success based on past performance, CBRE tracks how the life science industry is spreading out, and Organon's CEO discusses the company's biosimilars deal with Henlius.
BIO 2022 Notebook: How Is Industry Faring In Turbulent Times?
News and views from day one of the BIO annual meeting include reflections on how the biopharma industry is adjusting to current conditions. EY's annual Beyond Borders reports predicts continued success based on past performance, CBRE tracks how the life science industry is spreading out, and Organon's CEO discusses the company's biosimilars deal with Henlius.
Henlius Partners With Getz To Commercialize Adalimumab Biosimilar
Henlius and Getz Pharma have partnered to commercialize Henlius’ adalimumab biosimilar in 11 emerging markets in Asia, Africa and Europe.
Cancer Drug Developers Cry Foul As Costs Soar In China
Sheer volume of studies and fierce competition to recruit and enroll required numbers of patients in trials, even in a populous country like China, can quickly jack up new drug development costs.